Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
Cognition Therapeutics announced that the FDA has agreed on key aspects of a Phase 3 pivotal trial design for its drug candidate zervimesine (CT1812) targeting psychosis symptoms in dementia with Lewy bodies (DLB). This alignment supports using DLB psychosis as an approvable outcome, enabling the planned registrational study to begin in mid-2027. T…